Advances in Personalized Actinic Keratosis, Nonmelanoma Skin Cancer Treatments: Paul Nghiem, MD, PhD
Paul Nghiem, MD, PhD, discusses individualized therapies and the evolving role of AI in improving outcomes for actinic keratosis and related skin conditions.
Woburn, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), and ...
WOBURN, Mass., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results